SLAMF7
SLAMF7 Molecule Information
Name：SLAM family member 7
Target Synonym：Novel Ly9?CS1?CD_antigen=CD319?Membrane protein FOAP-12?CRACC?SLAMF7?Protein 19A?SLAM family member 7?CD2 subset 1?CD2-like receptor-activating cytotoxic cells
Number of Launched Drugs：1
Number of Drugs in Clinical Trials：3
Lastest Research Phase：Approved
SLAMF7 Molecule Synonym Name
SLAMF7,CD319,CS1,CRACC,19A,FOAP-12
SLAMF7 Molecule Background
SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.
SLAMF7 References
SLAMF7 Public Drug Information
| Name |
Research Code |
Research Phase |
Company |
First Brand Name |
First Approved Country |
First Indication |
First Approved Company |
First Approved Date |
Indications |
Clinical Trials |
| Elotuzumab |
HuLuc-63; BMS-901608; PDL-063 ,HuLuc63,BMS901608 |
Approved |
Abbvie, Bristol-Myers Squibb |
EMPLICITI |
fda |
Multiple myeloma (MM) |
BRISTOL MYERS SQUIBB |
2015-11-30 |
Multiple myeloma (MM) |
Details
|
SLAMF7 Clinical Drug Information
| Name |
Research Code |
Research Phase |
Company |
Indications |
Clinical Trials |
| UCART-CS1 |
UCART-CS1; UCART-38 |
Phase Ⅰ |
Cellectis, M.D. Anderson Cancer Center |
Multiple myeloma (MM) |
Details
|
| Azintuxizumab vedotin |
ABBV-838 |
Phase Ⅰ |
Abbvie |
Multiple myeloma (MM) |
Details
|
| CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology) |
|
Phase Not Specified |
Wuhan Bio-Raid Biotechnology, Tongji Hospital |
hematological malignancies |
Details
|
A-Z
